Paper Details

  1. Home
  2. Paper Details

Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre.

Author: AmbrosioniJuan, BerrocalLeire, BlancoJosé L, ChiviteIván, González-CordónAna, InciarteAlexy, LagunoMontserrat, LealLorna, MallolasJosep, MartinezEsteban, Martínez-RebollarMaría, MiróJosé M, Rojas LiévanoJhon, TorresBerta, UgarteAinoa, de LazzariElisa, de la MoraLorena

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This observational, retrospective study evaluated the real-world effectiveness, tolerability, and safety of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in adults with HIV. The study found that BIC/FTC/TAF achieved high rates of virological suppression in both treatment-naive and treatment-experienced patients. The medication was well-tolerated and safe, with high persistence observed at 6 months.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The use of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is mainly based on robust, pivotal clinical trials. OBJECTIVES: To provide data on clinical use of BIC/FTC/TAF in real life. PATIENTS AND METHODS: This was an observational, retrospective and single-centre study. ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/jac/dkab481

データ提供：米国国立医学図書館（NLM）

Bictegravir/emtricitabine/tenofovir Alafenamide: A Well-Stocked Oasis in the Desert of HIV Treatment

HIV treatment has evolved significantly, with new drug combinations offering improved efficacy and tolerability. This study explores the real-world experience with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in a large reference clinical center. Researchers meticulously analyzed data from a retrospective observational study, examining the effectiveness, tolerability, and safety of BIC/FTC/TAF in a diverse group of patients. The study demonstrates the high rates of virological suppression and good tolerability of BIC/FTC/TAF, providing valuable insights into its real-world application. This research, like a well-stocked oasis in the vast desert of HIV treatment, offers a promising treatment option for individuals living with HIV.

BIC/FTC/TAF: A Beacon of Hope in the Desert of HIV

This study provides a compelling case for BIC/FTC/TAF as a highly effective and well-tolerated treatment option for individuals living with HIV. The research, like a beacon guiding explorers through the desert, offers a glimmer of hope for individuals seeking a safe and effective treatment regimen. The study highlights the importance of ongoing research to understand the long-term effects of these therapies and to develop even more effective and personalized treatment options.

Navigating the Desert of HIV Treatment: A Journey of Hope and Support

HIV treatment has made significant progress, and this study provides further evidence of the effectiveness and safety of BIC/FTC/TAF. The research underscores the importance of providing comprehensive care and support to individuals living with HIV, empowering them to navigate their treatment journey and achieve optimal health outcomes. This study encourages continued research to refine treatment strategies and develop new therapies for a brighter future for individuals living with HIV.

Dr.Camel's Conclusion

This study provides a valuable oasis in the desert of HIV treatment research, offering a compelling case for BIC/FTC/TAF as a highly effective and well-tolerated treatment option for individuals living with HIV.

Date :
  1. Date Completed 2022-04-01
  2. Date Revised 2022-06-02
Further Info :

Pubmed ID

35040990

DOI: Digital Object Identifier

10.1093/jac/dkab481

Related Literature

Article Analysis
・Effects of emtricitabine and tenofovir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.